Derma Sciences De: (NASD: DSCI)
$13.81
0.05 (0.36%)
Volume 14,044
May 23 04:00 PM ET
Zacks Rank: 4-Sell 
| #4 |
Overview Quote
Stock Activity
| Day Low - High | 13.52 - 13.85 |
| 52wk Low - High | 8.80 - 14.92 |
| Previous Close | 13.76 |
| Avg. Volume | 66,141 |
| Industry | MED/DENTAL-SUPP |
| Market Cap | 220.43 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.01 |
| PE (Forward) | 0.00 |
| Current Year Est. | -1.63 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 4 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
121 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -1.63 |
| Current Quarter Estimate | -0.44 |
| Most Accurate Estimate | -0.44 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-13-2013 |
| EPS Last Year | -1.12 |
| Expected Earnings Growth | NA |
Company Description
Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE)
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.44 | -0.45 | -1.63 | -1.45 |
| Number of Estimates | 1 | 1 | 3 | 1 |
| Low Estimate | -0.44 | -0.45 | -1.70 | -1.45 |
| High Estimate | -0.44 | -0.45 | -1.58 | NA |
| Year Ago EPS | -0.23 | -0.24 | -0.97 | -1.63 |
| EPS Growth | -91.30% | -87.50% | -68.38% | 11.22% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| DERMA SCIENCES | DSCI | 13.76 | |
|
| LUXOTTICA ADR | LUX | 54.12 | |
|
| ALPHATEC HLDGS | ATEC | 1.91 | |
|
| CONMED CORP | CNMD | 33.28 | |
|
| COOPER COS | COO | 107.22 | |
|
| MWI VET SUPPLY | MWIV | 120.00 | |
|
| STERIS CORP | STE | 45.03 | |
|
| WEST PHARM SVC | WST | 67.34 | |
|
| ALIGN TECH INC | ALGN | 37.30 | |
|
| BARD C R INC | BCR | 105.28 | |
|
Sector:Medical>> Industry:MED/DENTAL-SUPP
COMPARE TICKER vs. Its Peers
Zacks Commentary
Company News for May 17, 2013
May 17, 2013
Company News for April 2, 2013
Apr 02, 2013
LabCorp Remains at Neutral
Jan 15, 2013
Quest Diagnostics Remains at Neutral
Jan 15, 2013
Zacks #1 Rank Additions for Tuesday
Dec 04, 2012
Zacks #1 Rank Additions for Thursday
Nov 29, 2012
Zacks #1 Rank Additions for Tuesday
Nov 20, 2012
Report for DSCI
May 21, 2013
Financials
| EPS TTM | -1.12 |
| Sales | 73 |
| Net Income | -16 |
| Price/Earnings | NA |
| Price/Book | 2.44 |
| Price/Cash Flow | NA |
| Price/Sales | 2.89 |
News
Why Derma Sciences May Be About to Take Off - TheMotleyFool
May 21, 2013
Earnings Scheduled For May 16, 2013 - Benzinga
May 16, 2013
This Metric Suggests You`re Right to Own Derma Sciences. - TheMotleyFool
May 1, 2013
Derma Sciences Begins Screening Patients in Second Phase 3 Trial with DSC127 for Healing Diabetic Foot Ulcers - Benzinga
Apr 25, 2013
Why Derma Sciences`s Earnings May Not Be So Hot - TheMotleyFool
Apr 25, 2013
A Hidden Reason That Derma Sciences`s Earnings Are Outstanding - TheMotleyFool
Apr 22, 2013
Derma Sciences Passes This Key Test - TheMotleyFool
Apr 15, 2013
Derma Sciences Beats Up on Analysts Yet Again - TheMotleyFool
Apr 2, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 3 |
| Average Target Price | 17.00 |
| Industry Rank by ABR | 121 out of 265 |
| Rank in Industry | 24 out of 29 |
